1 results match your criteria: "Department of Urology Hamamatsu University School of Medicine 1-20-1 Handayama Higashi-ku[Affiliation]"
The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Jpn J Clin Oncol
June 2012
Department of Urology Hamamatsu University School of Medicine 1-20-1 Handayama Higashi-ku, Hamamatsu, Shizuoka, Japan.
Objective: To assess the efficacy and safety of degarelix, a new gonadotropin-releasing hormone antagonist, for achieving and maintaining serum testosterone suppression (≤0.5 ng/ml) during the 12-month treatment of Japanese patients with prostate cancer.
Methods: This Phase II study was conducted as a multicentre, randomized, parallel-group, open-label study.